Table 3.
Tumor response assessment and correlation to KRAS mutational status
| All patients | All | WT | Codon 12 mutation | Codon 13 mutation | p-value |
|---|---|---|---|---|---|
|
No. of patients% |
201 |
128 |
58 |
15 |
|
|
100 |
63.6 |
28.9 |
7.5 |
||
|
ORR% |
55 |
63 |
49 |
23 |
0.008 |
|
95% CI |
(49–61) |
(54–71) |
(37–62) |
(8–51) |
(Chi-Square) |
|
DCR% |
85 |
88 |
81 |
77 |
0.29 |
| 95% CI | (80–90) | (80–92) | (68–89) | (49–93) | (Chi-Square) |
All patients. Percentages based on non-missing data, p-values for WT vs Codon 12 mutations vs codon 13 mutations; WT wild type; ORR overall response rate, DCR disease control rate.